Page last updated: 2024-08-26

sr141716 and Insulin Resistance

sr141716 has been researched along with Insulin Resistance in 51 studies

Research

Studies (51)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	23 (45.10)	29.6817
2010's	28 (54.90)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, B; Hu, N	1
Ahmed, L; Atkin, SL; Coady, AM; Dakroury, Y; Dawson, AJ; Elshewehy, AMM; Kilpatrick, ES; Sathyapalan, T	1
Choi, CS; Han, JH; Kim, IY; Kim, JE; Kim, KW; Kim, W; Lee, EK; Lee, YJ; Park, JH; Rho, JG; Seong, JK; Shin, H; Son, DH; Song, BJ; Yoon, J; Yoon, SG	1
de La Serre, CB; Grunewald, ZI; Kirkland, R; Lee, S; Ross, M	1
Han, JH; Kim, KW; Kim, W; Park, JY; Rho, JG; Seong, JK; Shin, H; Son, DH; Yoon, SH	1
Asare-Bediako, I; Bergman, RN; Clegg, DJ; Iyer, MS; Kabir, M; Kim, SP; Kolka, CM; Paszkiewicz, RL; Richey, JM; Stefanovski, D; Woolcott, OO; Wu, Q	1
Chen, W; Chen, Z; Li, S; Wang, L; Xue, N; Zheng, Z	1
Bajza, A; Literáti-Nagy, B; Literati-Nagy, Z; Mandl, J; Szilvássy, Z; Tory, K; Vígh, L	1
Choi, JM; Jin, SM; Kim, JH; Kim, KW; Lee, S; Oh, BJ; Park, CY; Park, SW; Yang, SJ	1
Bahekar, R; Jain, MR; Joharapurkar, AA; Kshirsagar, SG; Patel, KN; Patel, V; Srivastava, BK	1
Asare Bediako, I; Bergman, RN; Catalano, KJ; Chiu, JD; Hsu, IR; Ionut, V; Iyer, MS; Kabir, M; Kim, SP; Kolka, CM; Richey, JM; Stefanovski, D; Woolcott, OO; Wu, Q	1
Dopart, R; Kendall, DA; Lu, D	1
Cui, F; Wang, X; Yu, Q; Yue, H; Zeng, S	1
Davidova, A; Hambly, C; Hundal, HS; Irving, AJ; Lipina, C; Mitchell, SE; Speakman, JR; Storey-Gordon, E; Vaanholt, LM	1
Ganesh, S; Rustgi, VK	1
Ahmed, L; Atkin, SL; Coady, AM; Dakroury, Y; Elshewehy, AM; Kilpatrick, ES; Sathyapalan, T	1
Noll, G; Périat, D; Sudano, I	1
McGraw, TE; Motaghedi, R	1
Deedwania, P	1
Harrison, SA; Kashi, MR; Torres, DM	1
Awazawa, M; Hasegawa, C; Iwabu, M; Kadowaki, T; Katsuyama, H; Kubota, N; Kubota, T; Moroi, M; Nagai, R; Noda, T; Ohsugi, M; Sugi, K; Takamoto, I; Terauchi, Y; Tobe, K; Tokuyama, K; Ueki, K; Watanabe, T; Yamauchi, T	1
Cramer, A; Eckardt, K; Eckel, J; Horrighs, A; Koenen, M; Lehtonen, M; Platzbecker, B; Sell, H; Taube, A; Tennagels, N	1
Atkin, SL; Cho, LW; Coady, AM; Kilpatrick, ES; Sathyapalan, T	2
Galzin, AM; Guillot, E; Lacombe, A; Lefèvre, AL; Magnan, C; Migrenne, S; Pruniaux, MP	1
Faludi, G; Halmy, L; Purebl, G; Rihmer, Z	1
Ducluzeau, PH; Flamment, M; Gueguen, N; Malthièry, Y; Simard, G; Wetterwald, C	1
Balaraman, R; Chatterjee, A; Jain, MR; Mohapatra, J; Pandya, G; Patel, PR; Sharma, M; Singh, S	1
Shwarts, V	1
Biemer-Daub, G; Herling, AW; Miranville, A; Voss, MD	1
Lotersztajn, S; Mallat, A	1
Diane, A; Kelly, SE; Mangat, R; Novak, S; Proctor, SD; Russell, JC; Vine, DF; Wang, Y	1
Henriksen, EJ; Jacob, S; Lindborg, KA; Teachey, MK	1
Ambudkar, SV; Bátkai, S; Godlewski, G; Kunos, G; Liu, J; Makriyannis, A; Mukhopadhyay, B; Ohnuma, S; Osei-Hyiaman, D; Pickel, J; Tam, J; Vemuri, VK	1
Aouad, L; Bell-Anderson, KS; Caterson, ID; Farrell, GC; Larter, CZ; Phuyal, J; Sanz, FR; Williams, H	1
Botha, AJ; Crook, MA; Dar, A; McMahon, Z; Oben, J; Pendleton, S; Wierzbicki, AS	1
Bergman, RN; Catalano, KJ; Chiu, JD; Harrison, LN; Hsu, IR; Ionut, V; Iyer, M; Kabir, M; Kim, SP; Lottati, M; Richey, JM; Stefanovski, D; Woolcott, OO; Zheng, D	1
Cha, DR; Cha, JJ; Han, JY; Han, KH; Han, SY; Hyun, YY; Kang, YS; Kim, HW; Kim, JE; Kim, SH; Lee, JE; Lee, MH; Nam, DH; Song, HK	1
Bergman, RN; Catalano, KJ; Chiu, JD; Harrison, LN; Hsu, IR; Ionut, V; Kabir, M; Kim, SP; Kolka, C; Lottati, M; Richey, JM; Stefanoski, D; Woolcott, OO; Zheng, D	1
Backhouse, K; Bell, JD; Frost, GS; Robertson, MD; Russell-Jones, D; Sarac, I; Shojaee-Moradie, F; Stolinski, M; Thomas, EL; Umpleby, AM; Wright, J	1
Bastarrachea, RA; Comuzzie, AG; DiPatrizio, NV; Higgins, PB; Kamath, S; Parks, EJ; Piomelli, D; Vaidyanathan, V; Voruganti, VS	1
Arnone, M; Delgorge, C; Menet, C; Ravinet Trillou, C; Soubrié, P	1
Golay, A; Makoundou, V	1
Vinik, AI	1
Thompson, CA	1
Behn, A; Ur, E	1
Connell, JM; Ritchie, SA	1
Scheen, AJ; Van Gaal, LF	1
Saavedra, LE	1
Watson, KE	1
Berry, C; Bourassa, MG	1

Reviews

13 review(s) available for sr141716 and Insulin Resistance

Article	Year
Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. Clinics in liver disease, 2016, Volume: 20, Issue:2 Topics: Angiotensin Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Anticholesteremic Agents; Antioxidants; Cannabinoid Receptor Antagonists; Cholagogues and Choleretics; Fatty Acids, Omega-3; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metformin; Non-alcoholic Fatty Liver Disease; Orlistat; Pentoxifylline; Piperidines; Probiotics; Pyrazoles; Rimonabant; Synbiotics; Thiazolidinediones; Ursodeoxycholic Acid; Vitamin E	2016
The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism. International journal of cardiology, 2009, Jan-24, Volume: 131, Issue:3 Topics: Cannabinoid Receptor Modulators; Cardiovascular Diseases; Dyslipidemias; Endocannabinoids; Humans; Insulin Resistance; Lipid Metabolism; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Signal Transduction	2009
Current and emerging therapies in nonalcoholic fatty liver disease. Seminars in liver disease, 2008, Volume: 28, Issue:4 Topics: Animals; Antioxidants; Bariatric Surgery; Body Mass Index; Cannabinoids; Cholagogues and Choleretics; Comorbidity; Fatty Liver; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Lactones; Life Style; Metformin; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Thiazolidinediones; Treatment Outcome; Ursodeoxycholic Acid; Weight Loss	2008
[Association of obesity and depression]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2008, Volume: 10, Issue:4 Topics: Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Appetite Regulation; Bipolar Disorder; Circadian Rhythm; Cyclobutanes; Depression; Depressive Disorder, Major; Dietary Carbohydrates; Energy Intake; Ghrelin; Humans; Hypothalamo-Hypophyseal System; Insulin Resistance; Leptin; Obesity; Piperidines; Pituitary-Adrenal System; Pyrazoles; Rimonabant; Seasonal Affective Disorder; Sleep Wake Disorders; Surveys and Questionnaires; Weight Gain; Weight Loss	2008
[Adipose tissue inflammation and atherosclerosis]. Kardiologiia, 2009, Volume: 49, Issue:12 Topics: Adipokines; Adipose Tissue; Atherosclerosis; Chemotaxis; Cytokines; Endothelium, Vascular; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Macrophages; Metformin; Obesity; Piperidines; Pyrazoles; Rimonabant; Vasoconstrictor Agents	2009
Endocannabinoids and their role in fatty liver disease. Digestive diseases (Basel, Switzerland), 2010, Volume: 28, Issue:1 Topics: Animals; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Endocannabinoids; Fatty Liver; Humans; Hypertension, Portal; Inflammation; Insulin Resistance; Liver Cirrhosis; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant	2010
[New obesity and metabolic syndrome treatment: rimonabant]. Revue medicale suisse, 2006, Jan-04, Volume: 2, Issue:47 Topics: Eating; Humans; Insulin Resistance; Lipid Metabolism; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant	2006
The metabolic basis of atherogenic dyslipidemia. Clinical cornerstone, 2005, Volume: 7, Issue:2-3 Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Drugs, Investigational; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Intra-Abdominal Fat; Metabolic Syndrome; Obesity; Pioglitazone; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Thiazolidinediones	2005
The obesity epidemic and its cardiovascular consequences. Current opinion in cardiology, 2006, Volume: 21, Issue:4 Topics: Appetite Depressants; Body Fat Distribution; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; Humans; Inflammation; Insulin Resistance; Intra-Abdominal Fat; Lactones; Life Style; Lipid Metabolism; Metabolic Syndrome; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Thiazolidinediones; Waist-Hip Ratio	2006
The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2007, Volume: 17, Issue:4 Topics: Cardiovascular Diseases; Fatty Acids, Nonesterified; Humans; Inflammation; Insulin Resistance; Interleukin-6; Intra-Abdominal Fat; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Tumor Necrosis Factor-alpha	2007
[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes]. Revue medicale de Liege, 2007, Volume: 62, Issue:2 Topics: Anti-Obesity Agents; Bradykinin; Cannabinoids; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Follow-Up Studies; Glycated Hemoglobin; Heart; Humans; Insulin Resistance; Metabolic Syndrome; Obesity; Overweight; Piperidines; Placebos; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Triglycerides; Waist-Hip Ratio; Weight Loss	2007
Endocannabinoid system and cardiometabolic risk. Clinical pharmacology and therapeutics, 2007, Volume: 82, Issue:5 Topics: Abdominal Fat; Adipokines; Animals; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Endocannabinoids; Humans; Insulin Resistance; Lipids; Obesity; Overweight; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss	2007
Novel therapies for cardiometabolic risk reduction and implications for clinical practice. Reviews in cardiovascular medicine, 2007, Volume: 8 Suppl 4 Topics: Anti-Obesity Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Dyslipidemias; Exercise; Humans; Insulin Resistance; Life Style; Lipids; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Assessment; Risk Factors; Treatment Outcome; Weight Loss	2007

Trials

6 trial(s) available for sr141716 and Insulin Resistance

Article	Year
Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss. BMC endocrine disorders, 2017, Jul-14, Volume: 17, Issue:1 Topics: Alanine Transaminase; Anti-Obesity Agents; Body Mass Index; Cannabinoid Receptor Antagonists; Case-Control Studies; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Liver Diseases; Metformin; Obesity; Orlistat; Pioglitazone; Piperidines; Polycystic Ovary Syndrome; Prognosis; Pyrazoles; Receptor, Cannabinoid, CB1; Retrospective Studies; Rimonabant; Thiazolidinediones; Weight Loss	2017
Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome. Clinical endocrinology, 2016, Volume: 85, Issue:4 Topics: Body Mass Index; Cannabinoid Receptor Antagonists; Cytokines; Female; Hepatocyte Growth Factor; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Non-alcoholic Fatty Liver Disease; Obesity; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant	2016
Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS). Clinical endocrinology, 2009, Volume: 70, Issue:1 Topics: Adult; Androgens; Female; Humans; Insulin Resistance; Metformin; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Testosterone; Weight Loss	2009
Fatty acid flux and oxidation are increased by rimonabant in obese women. Metabolism: clinical and experimental, 2012, Volume: 61, Issue:9 Topics: Adiponectin; Aged; Breath Tests; Cannabinoid Receptor Antagonists; Cholesterol; Diet, Reducing; Energy Intake; Energy Metabolism; Fatty Acids; Female; Humans; Insulin Resistance; Leptin; Lipolysis; Lipoproteins, VLDL; Middle Aged; Obesity; Oxidation-Reduction; Palmitic Acids; Piperidines; Pyrazoles; Rimonabant; Triglycerides; United Kingdom; Weight Loss	2012
[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes]. Revue medicale de Liege, 2007, Volume: 62, Issue:2 Topics: Anti-Obesity Agents; Bradykinin; Cannabinoids; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Follow-Up Studies; Glycated Hemoglobin; Heart; Humans; Insulin Resistance; Metabolic Syndrome; Obesity; Overweight; Piperidines; Placebos; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Triglycerides; Waist-Hip Ratio; Weight Loss	2007
A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. Clinical endocrinology, 2008, Volume: 69, Issue:6 Topics: Adult; Female; Humans; Hyperandrogenism; Insulin Resistance; Metformin; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Testosterone; Weight Loss	2008

Other Studies

33 other study(ies) available for sr141716 and Insulin Resistance

Article	Year
Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed mice. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2017, May-04, Volume: 50, Issue:6 Topics: Animals; Blood Glucose; Body Weight; Calcium Channels; Calcium Channels, L-Type; Cannabinoid Receptor Antagonists; Diet, High-Fat; Glucose Intolerance; Insulin Resistance; Male; Mice, Inbred C57BL; Models, Animal; Muscle, Skeletal; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2017
Peripheral cannabinoid 1 receptor blockade mitigates adipose tissue inflammation via NLRP3 inflammasome in mouse models of obesity. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:9 Topics: Adipose Tissue; Animals; Brain; Cannabinoid Receptor Antagonists; Diabetes Mellitus, Experimental; Inflammasomes; Inflammation; Insulin Resistance; Macrophages; Male; Mice; Mice, Obese; NLR Family, Pyrin Domain-Containing 3 Protein; Obesity; Rimonabant	2018
Cannabinoid receptor type-1 partially mediates metabolic endotoxemia-induced inflammation and insulin resistance. Physiology & behavior, 2019, 02-01, Volume: 199 Topics: Animals; Body Weight; Cannabinoid Receptor Antagonists; Eating; Endotoxemia; Inflammation; Insulin Resistance; Lipopolysaccharides; Liver; Male; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction	2019
A novel peripheral cannabinoid 1 receptor antagonist, AJ5012, improves metabolic outcomes and suppresses adipose tissue inflammation in obese mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019, Volume: 33, Issue:3 Topics: 3T3 Cells; Adipose Tissue; Animals; CHO Cells; Cricetulus; Cytokines; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Humans; Hypoglycemic Agents; Inflammasomes; Inflammation; Insulin Resistance; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; RAW 264.7 Cells; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Weight Loss	2019
Activation of NPRs and UCP1-independent pathway following CB1R antagonist treatment is associated with adipose tissue beiging in fat-fed male dogs. American journal of physiology. Endocrinology and metabolism, 2019, 09-01, Volume: 317, Issue:3 Topics: Adipose Tissue; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Diet, High-Fat; Dogs; Gene Expression; Inflammation; Insulin Resistance; Male; Organelle Biogenesis; Receptor, Cannabinoid, CB1; Receptors, Adrenergic, beta; Receptors, Atrial Natriuretic Factor; Rimonabant; Thermogenesis; Uncoupling Protein 1; Weight Loss	2019
Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats. Naunyn-Schmiedeberg's archives of pharmacology, 2013, Volume: 386, Issue:8 Topics: Adipose Tissue; Animals; Animals, Newborn; Cannabinoid Receptor Antagonists; Fatty Liver; Female; Glucose Intolerance; Hyperlipidemias; Insulin Resistance; Liver; Male; Obesity; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Insulin; Rimonabant; Sodium Glutamate	2013
Synergic insulin sensitizing effect of rimonabant and BGP-15 in Zucker-obese rats. Pathology oncology research : POR, 2013, Volume: 19, Issue:3 Topics: Analysis of Variance; Animals; Blood Glucose; Disease Models, Animal; Drug Synergism; Glucose; Glucose Clamp Technique; Hyperinsulinism; Insulin; Insulin Resistance; Male; Obesity; Oximes; Piperidines; Pyrazoles; Rats; Rats, Zucker; Rimonabant	2013
Reduced food intake is the major contributor to the protective effect of rimonabant on islet in established obesity-associated type 2 diabetes. Yonsei medical journal, 2013, Volume: 54, Issue:5 Topics: Adiponectin; Adiposity; Animals; Cell Proliferation; Diabetes Mellitus, Type 2; Eating; Glucose Intolerance; Insulin Resistance; Insulin-Secreting Cells; Male; Piperidines; Pyrazoles; Rats; Rats, Inbred OLETF; Receptor, Cannabinoid, CB1; Rimonabant; Rosiglitazone; Thiazolidinediones	2013
Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice. Canadian journal of physiology and pharmacology, 2014, Volume: 92, Issue:12 Topics: Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Diet, High-Fat; Drug Synergism; Eating; Exenatide; Glucagon; Glucagon-Like Peptide 1; Insulin Resistance; Male; Mice, Inbred C57BL; Mice, Obese; Obesity; Peptides; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Venoms	2014
CB1R antagonist increases hepatic insulin clearance in fat-fed dogs likely via upregulation of liver adiponectin receptors. American journal of physiology. Endocrinology and metabolism, 2015, Oct-15, Volume: 309, Issue:8 Topics: Animals; Antigens, CD; Cannabinoid Receptor Antagonists; Cell Adhesion Molecules; Diet, High-Fat; Dogs; Glucose Clamp Technique; Insulin; Insulin Resistance; Insulysin; Liver; Male; Metabolic Clearance Rate; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, Adiponectin; Rimonabant; RNA, Messenger; Up-Regulation	2015
Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes. Cell stress & chaperones, 2016, Volume: 21, Issue:1 Topics: Animals; Cannabinoid Receptor Antagonists; Diabetes Mellitus, Type 2; Down-Regulation; Drug Inverse Agonism; Eating; Endocannabinoids; Endoplasmic Reticulum Stress; Humans; Inflammation; Insulin Resistance; Mitochondria; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction	2016
Effect of Intermittent Hypoxia and Rimonabant on Glucose Metabolism in Rats: Involvement of Expression of GLUT4 in Skeletal Muscle. Medical science monitor : international medical journal of experimental and clinical research, 2015, Oct-27, Volume: 21 Topics: Animals; Blood Glucose; Cannabinoid Receptor Antagonists; Gene Expression Regulation; Glucose; Glucose Transporter Type 4; Hypoxia; Immunohistochemistry; Insulin Resistance; Male; Muscle, Skeletal; Piperidines; Pyrazoles; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Sleep Apnea, Obstructive	2015
CB1 receptor blockade counters age-induced insulin resistance and metabolic dysfunction. Aging cell, 2016, Volume: 15, Issue:2 Topics: Age Factors; Animals; Cannabinoid Receptor Antagonists; Cell Line; Eating; Energy Metabolism; Gene Expression; Insulin Resistance; Male; Metabolic Diseases; Mice; Mice, Inbred C57BL; Piperidines; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Rimonabant	2016
[The endocannabinoid system]. Praxis, 2008, Apr-02, Volume: 97, Issue:7 Topics: Blood Glucose; Body Weight; Cannabinoid Receptor Modulators; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Endocannabinoids; Energy Metabolism; Europe; Humans; Insulin Resistance; Lipids; Obesity; Overweight; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2008
The CB1 endocannabinoid system modulates adipocyte insulin sensitivity. Obesity (Silver Spring, Md.), 2008, Volume: 16, Issue:8 Topics: 3T3-L1 Cells; Adipocytes; Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Cell Membrane; Dose-Response Relationship, Drug; Endocannabinoids; Glucose Transporter Type 4; Glycerides; Insulin; Insulin Resistance; Mice; Pertussis Toxin; Piperidines; Proto-Oncogene Proteins c-akt; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Insulin; Rimonabant	2008
Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. The Journal of biological chemistry, 2009, Jan-16, Volume: 284, Issue:3 Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Body Weight; Eating; Glucose; Insulin Resistance; Liver; Mice; Mice, Knockout; Mice, Obese; Muscle, Skeletal; Piperidines; Pyrazoles; Rimonabant	2009
Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. Diabetologia, 2009, Volume: 52, Issue:4 Topics: Adipocytes; Adipose Tissue; Arachidonic Acids; Cannabinoid Receptor Modulators; Cell Culture Techniques; Cell Differentiation; Endocannabinoids; Humans; Insulin Resistance; Muscle, Skeletal; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Receptor Cross-Talk; Receptor, Cannabinoid, CB1; Rimonabant	2009
Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice. American journal of physiology. Regulatory, integrative and comparative physiology, 2009, Volume: 296, Issue:4 Topics: Adiponectin; Animals; Anti-Obesity Agents; Dietary Fats; Disease Models, Animal; Eating; Glucose; Glucose Tolerance Test; Hyperinsulinism; Insulin; Insulin Resistance; Intra-Abdominal Fat; Lipids; Liver; Male; Mice; Mice, Knockout; Obesity; Piperidines; Pyrazoles; Rimonabant; Subcutaneous Fat; Weight Loss	2009
Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet. American journal of physiology. Endocrinology and metabolism, 2009, Volume: 297, Issue:5 Topics: Adiponectin; Animals; Body Composition; Diet, High-Fat; Dietary Fats; DNA; DNA, Mitochondrial; Eating; Energy Metabolism; Glucose; Insulin Resistance; Liver Function Tests; Male; Mitochondria, Liver; Oxygen Consumption; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Triglycerides; Weight Loss	2009
Involvement of adipokines in rimonabant-mediated insulin sensitivity in ob/ob mice. The Journal of pharmacy and pharmacology, 2009, Volume: 61, Issue:11 Topics: Adipokines; Adiponectin; Adipose Tissue; Adipose Tissue, White; Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Down-Regulation; Female; Gene Expression; Glucose Intolerance; Glucose Tolerance Test; Insulin; Insulin Resistance; Leptin; Mice; Mice, Knockout; Models, Animal; Nicotinamide Phosphoribosyltransferase; Obesity; Organ Size; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Retinol-Binding Proteins, Plasma; Reverse Transcriptase Polymerase Chain Reaction; Rimonabant; RNA, Messenger; Tumor Necrosis Factor-alpha	2009
Reversal of inflammation-induced impairment of glucose uptake in adipocytes by direct effect of CB1 antagonism on adipose tissue macrophages. Obesity (Silver Spring, Md.), 2010, Volume: 18, Issue:12 Topics: Adipocytes; Adipose Tissue; Animals; Anti-Obesity Agents; Blood Glucose; Cell Line; Culture Media, Conditioned; Diabetes Mellitus, Experimental; Dietary Fats; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin; Insulin Resistance; Interleukin-10; Lipopolysaccharides; Macrophages; Male; Mice; Obesity; Phosphorylation; Piperidines; Pyrazoles; Rats; Rats, Wistar; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Tumor Necrosis Factor-alpha	2010
Rimonabant-mediated changes in intestinal lipid metabolism and improved renal vascular dysfunction in the JCR:LA-cp rat model of prediabetic metabolic syndrome. American journal of physiology. Gastrointestinal and liver physiology, 2010, Volume: 299, Issue:2 Topics: Animals; Biomarkers; Blood Vessels; Body Weight; Cannabinoid Receptor Antagonists; Disease Models, Animal; Eating; Inflammation; Insulin Resistance; Intestinal Mucosa; Kidney Diseases; Kidney Glomerulus; Lipid Metabolism; Male; Metabolic Syndrome; Myocardial Ischemia; Piperidines; Prediabetic State; Pyrazoles; Rats; Rats, Mutant Strains; Renal Circulation; Rimonabant; Sclerosis; Thrombosis	2010
Effects of in vitro antagonism of endocannabinoid-1 receptors on the glucose transport system in normal and insulin-resistant rat skeletal muscle. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:8 Topics: Animals; Biological Transport; Female; Glucose; Hypoglycemic Agents; In Vitro Techniques; Insulin Resistance; Muscle, Skeletal; Piperidines; Pyrazoles; Quinoxalines; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant	2010
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. The Journal of clinical investigation, 2010, Volume: 120, Issue:8 Topics: Animals; Insulin Resistance; Leptin; Liver; Male; Mice; Mice, Inbred C57BL; Morpholines; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Triglycerides	2010
Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice. International journal of obesity (2005), 2011, Volume: 35, Issue:12 Topics: Adipose Tissue; Animals; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Glucose Intolerance; Glucose Tolerance Test; Inflammation; Insulin Resistance; Lipid Metabolism; Liver; Male; Mice; Obesity, Morbid; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2011
Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study. International journal of clinical practice, 2011, Volume: 65, Issue:6 Topics: Adult; Biomarkers; Cannabinoid Receptor Modulators; Cholesterol; Fatty Liver; Female; Humans; Hypercholesterolemia; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity, Morbid; Piperidines; Pyrazoles; Retrospective Studies; Rimonabant; Safety-Based Drug Withdrawals; Triglycerides; Weight Loss	2011
Large size cells in the visceral adipose depot predict insulin resistance in the canine model. Obesity (Silver Spring, Md.), 2011, Volume: 19, Issue:11 Topics: Adipocytes; Adiposity; Animals; Cell Size; Diet, High-Fat; Dogs; Insulin Resistance; Intra-Abdominal Fat; Linear Models; Male; Models, Animal; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2011
Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice. Endocrinology, 2012, Volume: 153, Issue:3 Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Gene Expression Regulation; Glucose; Insulin Resistance; Lipid Metabolism; Lipids; Male; Mice; Mice, Inbred C57BL; Piperidines; Podocytes; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; RNA Interference; RNA, Small Interfering	2012
CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs. American journal of physiology. Endocrinology and metabolism, 2012, May-01, Volume: 302, Issue:10 Topics: Abdominal Fat; Adiponectin; Animals; Blood Glucose; Body Composition; Cannabinoid Receptor Antagonists; Dietary Fats; Disease Models, Animal; Dogs; Energy Intake; Fatty Acids, Nonesterified; Glucose Clamp Technique; Insulin; Insulin Resistance; Liver; Male; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2012
Selective cannabinoid-1 receptor blockade benefits fatty acid and triglyceride metabolism significantly in weight-stable nonhuman primates. American journal of physiology. Endocrinology and metabolism, 2012, Sep-01, Volume: 303, Issue:5 Topics: Acetic Acid; Animals; Biotransformation; Body Composition; Carbon Isotopes; Deuterium; Fatty Acids; Insulin Resistance; Kinetics; Lipolysis; Liver; Male; Palmitic Acid; Papio; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Subcutaneous Fat, Abdominal; Triglycerides; Waist Circumference	2012
CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2004, Volume: 28, Issue:4 Topics: Animals; Body Weight; Diet; Dietary Fats; Eating; Energy Intake; Energy Metabolism; Insulin; Insulin Resistance; Leptin; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, Leptin; Recombinant Proteins; Rimonabant; Thinness	2004
Treatments for metabolic syndrome may expand. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2006, May-15, Volume: 63, Issue:10 Topics: Anti-Obesity Agents; Dietary Supplements; Humans; Insulin Resistance; Magnesium; Metabolic Syndrome; Piperidines; Pyrazoles; Rimonabant; Risk Factors	2006
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes. Current atherosclerosis reports, 2008, Volume: 10, Issue:2 Topics: Antihypertensive Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Diabetic Angiopathies; Humans; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Life Style; Myocardial Infarction; Obesity; Pioglitazone; Piperidines; Platelet Aggregation Inhibitors; Prediabetic State; Pyrazoles; Ramipril; Rimonabant; Risk Assessment; Thiazolidinediones; Triglycerides; Weight Loss	2008